首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
admin
2017-03-15
52
问题
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought grew worse. According to newly released statistics from the Food and Drug Administration (FDA), it approved only 20 new drugs, down from 36 in 2004. Only once in last 10 years has the number of newly approved drugs been lower than last year’s figure.
The dry spell in 2005 came even as spending on research by the industry reached a new high, passing $38 billion. And in a rarity, several major companies failed to win approval for a new drug invented in their own labs, including Pfizer, Eli Lilly and Johnson & Johnson.
The decline in drug development came as scientists in and outside the companies were making great strides in genomics and other sorts of basic research into the way diseases develop, opening many potential new targets for treatment. Yet such progress in the laboratory has not translated so far into many new drugs on the market.
Some analysts say that the drug industry is in a cyclical trough, and that the number of new drugs—not just new applications for drugs already on the market—will start rising within a few years as research investments begin to pay off. But the FDA and the companies seem to agree that the process for testing and developing new drugs needs improvement.
"Our concern is that the development process itself is not keeping up at a fast enough pace to match the progress on the discovery end," said Dr. Scott Gottlieb, the agency’s deputy commissioner for medical and scientific affairs.
The FDA is looking for ways to speed the approval of new treatments—like approving drugs based on "surrogate endpoints," whether, for example, a cancer drug causes tumors to shrink instead of whether it prolongs the life of patients. It was on such a basis that the FDA last month approved Nexavar, a Bayer drug for treating kidney cancer.
But like finding new treatments, diagnosing the problem of drug development is easier than figuring out a solution. Even as the FDA looks for ways to speed the testing of new treatments, members of Congress and some consumer groups are calling for even more testing before drugs are approved.
The low output from research last year was even worse than the top-line figures might indicate. In 2004, important cancer treatments including Avastin, by Genentech, and Tarceva, through a partnership of Genentech and OSI Pharmaceuticals, were among the therapies that regulators allowed onto the market. The drugs that were approved were mostly for rare diseases like chronic iron overload, a condition for which the Novartis medicine Exjade received clearance.
In the meantime, the agency delayed approval of prominent new treatments like Pargluva, a diabetes drug from Bristol-Myers Squibb and Merck, and Exubera, a form of inhaled insulin from Pfizer.
The paucity of new products is a big reason that the stock prices of large drug makers have tended to fare poorly in recent years. Shares of Pfizer, the industry leader, for example, reached a peak of $49 in July 2000 and have trended downward since, closing yesterday at $24.44.
The drought in new drugs has led some industry executives to complain that the FDA is denying approval to good new treatments because of the criticism the agency has faced from lawmakers over Vioxx. Merck stopped selling its arthritis painkiller Vioxx in 2004 after a clinical trial showed that it increased the risks of heart attacks and strokes in patients taking it for 18 months or longer. Some other studies found heart attack risks as early as 2000, and the FDA has been criticized for not forcing Merck to withdraw the drug earlier or to warn doctors prominently of such risks.
Researching and developing a drug is a long and arduous process. Genentech’s work leading to Avastin, for example, began in 1989—15 years before the drug’s approval. Scientists first identify the cellular process of disease within the body. They may search for proteins that cancerous tumors release in order to spread, or receptors on the surface of a cell that become the targets of viruses.
The drug company then searches for chemical compounds or proteins that are able to interact with the targets the scientists have found—without damaging cells in other parts of the body. If a treatment appears to have therapeutic effects in test-tube and animal trials, the companies then move on to Phase I human testing, when a handful of healthy volunteers are given the therapy to make sure that it is safe enough for wider testing. In Phase II testing, the drug is tried on a few dozen to a few hundred patients for safety and effectiveness.
Finally, in Phase III development, the drug is tested in large-scale trials with as many as several thousand patients to demonstrate its effectiveness and to search for rarer side effects.
If the treatment is shown to be unsafe or ineffective at any stage, it fails development and is put aside.
According to a report in December from Merrill Lynch, the number of potential new drugs in Phase I and II testing has nearly doubled in the last decade, to 1,971 in 2004 from 1,010 in 1995. But that has not translated into success in Phase III development; the number of drugs in Phase III has been flat at fewer than 400.
"R&D statistics over the past decade have been disappointing," Merrill’s analysts wrote in their report. Still, the analysts predicted that companies would continue to increase research spending and expand their pipelines of early-stage drugs.
What do we know about "surrogate endpoints", based on the 6th paragraph?
选项
A、It is a principle favored by pharmaceutical companies.
B、It is a criterion FDA adopted to accelerate the approval of new medicines.
C、It championed the goal to lengthen cancer patients’ life rather than the effect on cancer.
D、It was a time-honored practice of FDA to carry out approval for treatments.
答案
C
解析
转载请注明原文地址:https://kaotiyun.com/show/GCSO777K
本试题收录于:
NAETI高级口译笔试题库外语翻译证书(NAETI)分类
0
NAETI高级口译笔试
外语翻译证书(NAETI)
相关试题推荐
Givingthechildproblemshecannotsolvewillonlyfrustratehim.
ThehappiestpeopleintheworldmayliveinScandinavia,anewstudysuggests.That’saccordingtotheUnitedNationsGeneralA
Theschoolisgoingthe________miletocreatethenextgenerationofsportingstarsthankstoitsuniquedevelopmentprogram.
中国经济高速发展,需要大量的矿产品及相关的能源与原材料加工制品。每年消耗的矿石量达60多亿吨,位居世界前列。中国政府为实现经济的可持续发展,在矿产资源勘查、开发领域制定了一系列的法律、法规和政策,形成了既适合中国国情又基本与国际接轨的矿产资源勘查
主席先生,中国代表团很高兴与其它代表团相聚日内瓦,共同审议信息社会世界峰会的有关筹备事宜。首先,请允许我代表中国代表团衷心祝贺你当选峰会筹备委员会主席。//我希望,在你的领导下,峰会的筹备工作能在本次会议上有一个良好的开端和基础。中国代表团将与你
A、TheFutureofSugarIndustryinCentralAmericaB、UnemploymentinLatinAmericaC、ReformsinSugarIndustryinNorthAmericaD
Listentothefollowingpassage.WriteashortEnglishsummaryofaround150—2,00wordsofwhatyouhaveheard.Youwillhearth
Iwanttodiscusssomeideasabouthowwemanageunderground【B1】______.Ifweonlytakeasmuchoutascomesin,we’renotgoing
Thehunter-gatherertribesthattodayliveasourprehistoric【M1】______humanancestorsconsumeprimarilyavegetabledi
随机试题
人生目的主要回答:()
慢性胃炎最常见的临床表现是()
公民甲向乙房地产公司销售部工作人员缴纳了2万元定金,并签订了一份协议。其商定好以60万元的价格购买一套房屋,并约定一个月后签订正式购房合同。一个月后甲凑足购房费用,欲和乙房地产公司签订正式购房合同。但此时房价已经大幅度上涨,原来60万元的房屋可以卖至80万
注册会计师担任某项审计业务的外勤负责人,如在执业过程中发现自己无法胜任,则应要求其所在会计师事务所( )。下列各项中,属于注册会计师违反职业道德规范的是( )。
CPU不可以直接访问的存储器有()。
碘是人体必需的元素,但是统一在食盐中添加碘的方式可能导致“补碘”过量,某些非缺碘地区增售无碘盐,人们可以根据具体情况自主调节摄碘量。该材料体现的哲理有()。
人民警察的(),不仅指人民警察必须具有相应的文化程度(学历),而且要求人民警察具有良好的文化修养。
关于民事权利的说法,正确的是()。
在一次校园活动中拍摄了很多数码照片,现需将这些照片整理到一个PowerPoint演示文稿中,快速制作的最优操作方法是:
A、Red.B、Black.C、White.D、Notalloftheabove.D对话中未说明到底哪种颜色适合女孩,所以选D。
最新回复
(
0
)